Group I Trans-Splicing Introns for HIV Reservoir Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection, such as HAART, fail to completely eliminate the virus due to the presence of persistently infected cell reservoirs, leading to ongoing infection and the development of resistant mutations, and alternative approaches like stem cell transplantation require CCR5-deficient donors and immune ablation therapies.
Innovation Solution
The use of Group I trans-splicing introns as anti-viral agents that target conserved HIV genomic sequences, causing infected cells to undergo apoptosis upon infection, thereby preventing viral proliferation and re-establishment, and the use of autologous stem cells transformed to express these introns to reconstitute an immune system incapable of supporting HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART treatment is used to suppress HIV infection, then immune function is restored and viral replication is suppressed, but the virus cannot be completely eliminated due to persistently infected cell reservoirs
Solution Approach 1:
The patent extracts and targets the specific conserved genomic sequences of HIV (such as the tRNA primer binding site) using intron-based ribozymes. By designing guide sequences that specifically hybridize to these conserved viral regions, the system selectively eliminates viral RNA without affecting host cell functions, thereby removing the virus from reservoirs while preserving immune function.
Solution Approach 2:
The patent changes the molecular parameters of HIV by introducing introns with specific guide sequences that alter viral RNA processing. The introns are designed with optimized guide sequence lengths, GC content, and secondary structure characteristics to maximize binding affinity and catalytic efficiency against conserved viral sequences, enabling complete viral elimination rather than mere suppression.
2Adaptability or versatility
If stem cell transplantation is used to treat HIV infection, then new immune cells are provided, but the procedure requires CCR5-deficient donors and immune ablation therapies
Solution Approach 1:
The patent enables autologous stem cell therapy where a patient's own stem cells are genetically modified ex vivo to express anti-HIV introns, then retransfused into the same patient. This self-service approach eliminates the need for CCR5-deficient donors and complex immune ablation protocols, simplifying the treatment procedure while maintaining the ability to replace and reconstitute the immune system with virus-resistant cells.
3Reliability
If trans-splicing introns are used to target HIV genomic sequences, then infected cells undergo apoptosis upon infection, but the mechanism requires specific guide sequence design and RNA processing
Solution Approach 1:
The patent incorporates anti-HIV introns into the genome of stem cells before infection occurs. These introns are designed with pre-configured guide sequences that will specifically recognize and bind to conserved HIV genomic sequences upon viral infection. The introns are positioned and structured in advance to ensure immediate apoptotic response when the virus attempts to infect the cell, eliminating the need for complex real-time detection systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces and potentially eliminates HIV reservoirs, providing a long-lasting cure by ensuring infected cells die upon infection, thereby stabilizing viral load and reducing the need for ongoing antiviral therapies.
Implementation Method 1
The trans-splicing Group I intron reaction targets an RNA molecule through the use of antisense guide sequences that hybridize with the target RNA
Implementation Method 2
This intron excised itself from the highly purified mature rRNA in a solution of magnesium and guanosine in a cell-free system. Later, this intron was configured to splice together RNA on two separate molecules by two successive trans-esterification reactions
Implementation Method 3
causing infected cells to undergo apoptosis upon infection, thereby preventing viral proliferation
Data Source
AI summary
Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.